Vitamin $B_{12}$ deficiency in infants secondary to maternal causes

Nadia Roumeliotis MD, David Dix MB, Alisa Lipson MD

Case 1

A nine-month-old female infant presented with a two-day history of vomiting, diarrhea and decreased urine output, along with a three-month history of lethargy and reduced tone. Her early development had been normal, but regression of skills had begun three months before presentation, with a loss of gross motor skills progressing to a loss of head control. The child had been exclusively breastfed until solids were slowly introduced over the last month. Her family was of South-East Asian ethnic origin, and her mother was a strict life-long vegan who took prenatal vitamins during pregnancy.

On examination, the baby was sleepy and pale. Her weight was 6.65 kg (< 3rd percentile), height was 69 cm (25th percentile) and head circumference was 41 cm (<3rd percentile). The liver edge was 3 cm below the costal margin. The splenic tip was palpable. Her axial and peripheral muscle tone was decreased, with frog-like posture of both legs. No antigravity power was exhibited. Reflexes were 3+ in her lower extremities and 2+ in her upper extremities. She was able to fix visually but did not follow.

Laboratory investigations showed a hemoglobin level of 35 (range 103–135) g/L, leucocyte count of 3.4 (range 5–16) × 10^9/L and platelet count of 149 (range 200–550) × 10^9/L. The mean corpuscular volume was 95.3 (range 70–86) fl and reticulocyte count was 35 (range 20–80) × 10^9/L. The blood smear showed pancytopenia with severe leukoerythroblastic change, dysplastic red blood cells and rare hypersegmented neutrophils; it appeared severely megaloblastic overall (Figure 1). The albumin level was 18 (range 34–42) g/L. Vitamin $B_{12}$ level was less than 37 (range 133–695) pmol/L (lower reporting limit), and the folate level was 14 (range 7–36) nmol/L. A bone marrow biopsy showed morphological changes consistent with megaloblastic anemia. Magnetic resonance imaging (MRI) of the patient’s brain showed generalized atrophy. Metabolic and biochemical investigations, including acylcarnitine profile, plasma amino acid and urine organic acids, showed abnormalities consistent with dietary protein deficiency.

Because the infant had been mostly breastfed with limited solid intake, we examined the mother. Her complete blood count was normal, but her vitamin $B_{12}$ level was low at 63 (adult reference range 133–695, deficient < 107) pmol/L. Review of the mother’s prenatal blood work indicated a normal hemoglobin level, with a normal mean corpuscular volume. The infant’s anemia was managed initially with a slow transfusion of packed red blood cells. Intramuscular injections of vitamin $B_{12}$ (1000 µg) were given daily for seven days, then weekly for the next month, along with oral iron supplementation. Nasogastric feeding with formula was initiated because of poor suck, and breastfeeding was maintained for comfort. The mother was started on oral $B_{12}$ supplementation.

Five months later, the infant was consuming solid baby food and infant formula, and her growth parameters had improved. Her muscle tone and neurologic status had also improved. The complete blood count and $B_{12}$ levels were normal.

Key points

- One in twenty women of child-bearing age in Canada has inadequate levels of vitamin $B_{12}$.
- Infant $B_{12}$ sufficiency is related to maternal levels via neonatal stores at birth and the amount in breast milk.
- Vitamin $B_{12}$ deficiency in infants, although rare, is important to recognize because treatment can prevent severe developmental delay and neurologic sequelae.
- Prevention includes dietary supplementation for mothers and their breastfed infants who are at risk of vitamin $B_{12}$ deficiency.
Case 2

A seven-month-old male infant presented with a two-week history of lethargy and a loss of previously acquired milestones, as well as a two-month history of diarrhea and being generally unwell. He had been seen by his family doctor on multiple occasions and treated with antibiotics with no identified source of infection. He was exclusively breastfed. The family was white, and the mother had no dietary restrictions.

On examination, the child was lethargic. His weight was 7.5 kg (10th–25th percentile), and his head circumference was 43.75 cm (25th–50th percentile). His length was within the normal limits. On neurologic examination, he had generalized decreased tone, with brisk reflexes in the extremities. The rest of the examination was unremarkable.

Laboratory investigation showed a hemoglobin level of 46 (range 103–135) g/L, leukocyte count of 4.4 (range 5–16) × 10⁹/L, platelet count of 88 (range 200–550) × 10⁹/L and a neutrophil count of 0.37 (range 1.0–8.5) × 10⁹/L. The mean corpuscular volume was 91.3 (range 70–86) fL, and the reticulocyte count was 15 (range 20–80) × 10⁹/L. The blood smear showed pancytopenia with evidence of red blood cell macrocytosis. No blast cells were seen. A bone marrow biopsy showed megaloblastic anemia in keeping with vitamin B₁₂ deficiency. The vitamin B₁₂ level was less than 37 (133–695) pmol/L, and the folate level was 30 (range 7–36) nmol/L. An MRI of the patient’s brain showed generalized symmetric cortical atrophy and incomplete subcortical myelination (Figure 2). The metabolic investigations did not show evidence of an inborn error of metabolism.

Because the patient was exclusively breastfed, the mother was examined and found to have antibodies to intrinsic factor and gastric parietal cells, and undetectable vitamin B₁₂ levels. A diagnosis of maternal pernicious anemia was made.

Intramuscular injections of vitamin B₁₂ (1000 µg) were administered daily to the child for 10 days, followed by monthly injections, along with iron supplementation. His muscle tone slowly improved. After one week of treatment, the infant was consuming solid food, and breastfeeding was decreased. The infant’s complete blood count and vitamin B₁₂ levels normalized. The mother was referred to a hematologist and began injections of vitamin B₁₂ subcutaneously for four weeks, followed by monthly injections indefinitely.

Worldwide, vitamin B₁₂ deficiency is an important cause of infant morbidity, especially in the Indian subcontinent, Mexico, Central America and certain regions of Africa. Although relatively rare in the developed world, vitamin B₁₂ deficiency in infants is important to recognize because early treatment can prevent potentially devastating neurologic and developmental sequelae, such as hypotonia and developmental regression.
Infant vitamin B\textsubscript{12} deficiency, in most cases, results from a maternal deficiency. Maternal causes of infant deficiency can be broadly divided into deficient maternal diet or maternal pernicious anemia in a breastfed infant (Table 1), because infant formulas are supplemented with B\textsubscript{12}. Other more rare causes in children include surgical removal of the stomach and/or distal ileum, autoimmune gastritis, bacterial overgrowth, ileal disease (Crohn disease), exocrine pancreatic insufficiency and Whipple disease.

Maternal dietary deficiency is usually due to a vegetarian diet (which excludes meat, fish and fowl) or vegan diet (excluding also all dairy and eggs), dietary practices that are becoming increasingly popular for religious, humanitarian and health reasons in the developed world. Maternal pernicious anemia is less common as a cause. In both situations, if the mother has vitamin B\textsubscript{12} deficiency during pregnancy, the newborn will have low B\textsubscript{12} stores, and depletion will occur rapidly without supplementation. If maternal breast milk is deficient in B\textsubscript{12}, the infant will have inadequate daily intake to maintain B\textsubscript{12} stores.

A recent study of the prevalence of B\textsubscript{12} deficiency in an unselected group of pregnant women in Canada found that about 1 in 20 women were biochemically deficient for vitamin B\textsubscript{12} in early pregnancy. Similarly, results of the Canadian Health Measures Survey revealed that about 5% of women aged 20–45 years were deficient in vitamin B\textsubscript{12}, and 20% had marginal stores. Another study involving pregnant adolescents found that about half had suboptimal vitamin B\textsubscript{12} levels. The cause of deficiency in these women, and the sequelae in infants, was not reported in these studies. There is no literature on the prevalence of vitamin B\textsubscript{12} deficiency in infants.

In a 2001 survey by the National Institute on Nutrition, 4% of Canadians identified themselves as vegetarians; there are little data, however, on the rate of vegan diets. The prevalence of vegetarian or vegan diets in pregnant and lactating mothers in Canada is unknown. In an Ontario study involving predominantly lacto–ovo vegetarian East Indian women (mean age 33 ± 7 yr), 7.8% were found to be deficient in vitamin B\textsubscript{12}. Vegetarian mothers have been shown to have evidence of vitamin B\textsubscript{12} deficiency, regardless of whether or not they were lactating.

There is a positive relation between maternal and breast-fed infant vitamin B\textsubscript{12} deficiency linked to low B\textsubscript{12} levels in breast milk. According to a study by Specker and colleagues, vitamin B\textsubscript{12} milk concentrations less than 360 pmol/L, approximately corresponding to a maternal serum B\textsubscript{12} of less than 300 pmol/L, could result in an infant who is biochemically deficient in vitamin B\textsubscript{12}. It remains to be determined what maternal serum vitamin B\textsubscript{12} level is sufficient for exclusive breastfeeding.

The prevalence of pernicious anemia in Canada is not reported in the literature. In the United States, it has been estimated to affect 150 per 100 000 adults, with peaks between 50 and 60 years of age. These numbers do not reflect the prevalence of pernicious anemia in women of child-bearing age.

**Mechanism of action**

Vitamin B\textsubscript{12} (cobalamin) is essential for folate metabolism and DNA synthesis, acting as a cofactor for two key enzymatic reactions. Deoxyadenosylcobalamin, one of the coenzyme forms of cobalamin, is a cofactor for methionine synthase, the enzyme which converts homocysteine to methionine. If this coenzyme is lacking, homocysteine accumulates, leading to megaloblastic anemia and neurologic sequelae. Cobalamin is also a cofactor for methylmalonyl CoA mutase, the enzyme that converts methylmalonyl CoA to succinyl CoA. The latter is needed for the metabolism of odd-chain fatty acids and purine and pyrimidine synthesis. Methylmalonic aciduria and defective amino acid synthesis results from the lack of the cobalamin cofactor, clinically leading to pancytopenia, metabolic acidosis and hypotonia.

### Table 1: Characteristics of B\textsubscript{12} deficiency in infants

<table>
<thead>
<tr>
<th>Causes</th>
<th>Infants whose mothers’ diets are deficient in B\textsubscript{12}</th>
<th>Infants whose mothers have pernicious anemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Presentation</strong></td>
<td>Macrocystic anemia, failure to thrive, lethargy, hypotonia, hyperreflexia, loss of milestones, microcephaly, irritability, glossitis\textsuperscript{a,b,11}</td>
<td>Megaloblastic anemia in infant</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>Megaloblastic anemia in infant</td>
<td>Low serum B\textsubscript{12} in infant and mother</td>
</tr>
<tr>
<td></td>
<td>Maternal history of diet low in B\textsubscript{12}</td>
<td>Maternal history of diet low in B\textsubscript{12}</td>
</tr>
<tr>
<td></td>
<td>Positive Schilling test in mother or history of maternal pernicious anemia</td>
<td>Positive Schilling test in mother or history of maternal pernicious anemia</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Cyanocobalamin (intramuscular or intravenous injection) daily, then tapered to weekly and monthly\textsuperscript{17}</td>
<td>Early introduction of B\textsubscript{12}-fortified foods (e.g., cereals or formula)</td>
</tr>
<tr>
<td></td>
<td>Early introduction of B\textsubscript{12}-fortified foods (e.g., cereals or formula)</td>
<td>Maternal oral or intramuscular cyanocobalamin</td>
</tr>
<tr>
<td><strong>Prevention</strong></td>
<td>Maternal oral supplementation of B\textsubscript{12}</td>
<td>Early introduction of B\textsubscript{12}-fortified foods†</td>
</tr>
<tr>
<td></td>
<td>Oral supplementation of vitamin B\textsubscript{12}</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Early introduction of B\textsubscript{12}-fortified foods</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a}For example, vegan or vegetarian diets.  
\textsuperscript{b}We are unaware of recommendations on oral B\textsubscript{12} supplementation for prevention in infants whose mothers have pernicious anemia.
Vitamin B₁₂ is not synthesized by the body and must therefore be ingested through diet. In the stomach, it binds to intrinsic factor, a protein synthesized by parietal cells, which is lacking in pernicious anemia because of autoimmune injury. The B₁₂–intrinsic factor complex is then absorbed into the circulation in the distal ileum.

Clinical presentation
The clinical features of infant vitamin B₁₂ deficiency from either maternal dietary deficiency or maternal pernicious anemia do not appear to depend on cause, but rather on the severity of B₁₂ deficiency, with many children being asymptomatic and presenting only with megaloblastic anemia found on blood work. When infants show clinical effects, the effects usually present between 2 and 12 months of age, when neonatal stores have been depleted and dietary vitamin B₁₂ is inadequate. Typically, symptoms of vitamin B₁₂ deficiency include poor feeding, weight loss and irritability; glossitis and infections have also been reported.

It is the neurologic manifestations, however, that are the most concerning. As illustrated by the two infants we described, central nervous system symptoms can be severe, beginning with irritability, apathy, lethargy and gross motor developmental regression. Head circumference measurements fall off the growth curve, indicating slowing of brain growth. Patients progress to hypotonia with hyperreflexia, and exhibit choreoathetoid movements. The mechanisms of central nervous system involvement are not clearly understood. Demyelination, delayed myelination, impaired methylation and lactate accumulation in peripheral nerves, spinal cord and cerebrum have all been proposed.

Diagnosis
The diagnosis of vitamin B₁₂ deficiency in infants can be easily suspected when macrocytic anemia is seen on a complete blood count. This test is usually part of the initial battery in the workup of an ill child. The diagnosis is confirmed by determining serum vitamin B₁₂ concentration. Treatment should not be delayed to wait for the vitamin B₁₂ results, because the neurologic sequelae can be corrected. In our patients, bone marrow aspiration was also performed, which confirmed the diagnosis, but this would not be necessary for mildly affected patients.

There are case reports of infant vitamin B₁₂ deficiency being diagnosed on newborn screening. In maternal vitamin B₁₂ deficiency, the upstream products homocysteine and methylmalonic acid accumulate and can be transmitted to the fetus. Raised levels of these products have been detected on newborn screening of infants with low vitamin B₁₂ stores, before the development of megaloblastic anemia in the infant. Both of our patients had normal newborn screens, however. Thus, screening for methylmalonic acid cannot be relied upon to detect infants with low vitamin B₁₂ stores. Indeed, the role of neonatal screening for vitamin B₁₂ deficiency remains unclear. A normal maternal blood count is not a reliable marker for deficiency in the infant.

If maternal vitamin B₁₂ deficiency is suspected, a complete blood count and serum vitamin B₁₂ assay in the mother are diagnostic. If the mother’s history does not suggest a dietary deficiency, a Schilling test should be completed for pernicious anemia.

Treatment
Diverse recommendations exist for initial and maintenance therapy of vitamin B₁₂ deficiency in adults, and no clear guidelines are available for children. Studies involving adults have reported equivalent efficacy of oral and intramuscular replacement therapy. Oral replacement therapy, however, is likely to be less reliable in infants.

### Table 2: Recommendations for B₁₂ intake in women

<table>
<thead>
<tr>
<th>Group</th>
<th>No risk factors for anemia</th>
<th>With dietary risk factors* for anemia</th>
<th>With pernicious anemia†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonpregnant women</td>
<td>2.4 µg/d¹⁹,²⁰</td>
<td>3 servings of B₁₂-rich foods or 5–10 µg/d</td>
<td>Monthly 1000 µg via IM injection</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>2.6 µg/d¹⁹,²⁰</td>
<td>~4 servings per day of B₁₂-rich foods†</td>
<td>Monthly 1000 µg via IM injection</td>
</tr>
<tr>
<td>Lactating women</td>
<td>2.8 µg/d²⁰</td>
<td>~4 servings per day of B₁₂-rich foods/d†</td>
<td>Monthly 1000 µg via IM injection</td>
</tr>
</tbody>
</table>

Note: IM = intramuscular.
*For example, vegan or vegetarian diets.
†No specific recommendations are made with regards to the recommended daily intake of B₁₂ in vegetarian or vegan pregnant and lactating women.
Practice

because they are more prone to regurgitation and vomiting.

In adults with severe B₁₂ deficiency with neurologic manifestations, experts recommend 1000 µg cyanocobalamin given via intramuscular injection daily for a week, followed by weekly injections for a month, then every third month.¹⁸ The use of oral cyanocobalamin in patients with neurologic symptoms, adult or pediatric, has not been adequately assessed.¹⁷ Consensus guidelines for optimal replacement therapy in deficient pediatric patients are required. Replacement therapy at adult doses was administered by the intramuscular route in both of the infants described in this article, according to common practice for severe B₁₂ deficiency with neurologic symptoms.

In patients with pernicious anemia, adult or pediatric, lifelong replacement with cyanocobalamin is required. Common practice for adults in North America and Europe is monthly 1000 µg cyanocobalamin via intramuscular injection, which was the treatment regimen for the mother in Case 2. Treatment regimens vary widely, however, because oral cyanocobalamin has also been shown to be efficacious for pernicious anemia.¹⁹ The British Columbia Guidelines and Protocols Advisory Committee recommends oral B₁₂ replacement of 1000 µg daily.²⁰ Considerations when initiating B₁₂ therapy include providing adequate iron supplementation for the increased red blood cell production and also the potential for unmasking a concurrent folate deficiency.

Prevention

To prevent vitamin B₁₂ deficiency, health care providers caring for pregnant or lactating mothers and their newborns should take a full dietary history and consider vitamin B₁₂ status, particularly in vegetarian mothers and their infants.

Health Canada recommends a daily intake of 2.4 µg vitamin B₁₂ for all women.²⁰ Dietary guidelines in North America recommend a daily dietary vitamin B₁₂ intake for pregnant and lactating women of 2.6 and 2.8 µg B₁₂, respectively.²⁰,²¹ A new food guide for vegetarians, suggested by Messina and colleagues,²² recommends that vegetarians consume at least three servings of vitamin B₁₂-rich foods daily or supplement with 5–10 µg vitamin B₁₂ daily. Recommendations for vegetarian pregnant and lactating women are less specific.²² The recommendations for vitamin B₁₂ intake for women are summarized in Table 2.

A recent position statement by the Canadian Paediatric Society suggests that all solely breastfed infants of vegan mothers should be given 5–10 µg vitamin B₁₂ daily through oral vitamin supplements or at least three servings of food rich in vitamin B₁₂ to prevent deficiency.²³ Vitamin B₁₂ is naturally found in animal products, especially meat, as well as in dairy products and eggs. Other sources include fortified foods, such as infant formulas, cereals and soy products (Table 3).²⁴ There are no current recommendations for the supplementation of infants born to mothers with pernicious anemia.

In the two patients described in this article, their mothers were following the current practice of exclusively breastfeeding for the first six months. The late introduction (after six months of age) of solid food rich in vitamin B₁₂, such as fortified infant cereals and those mentioned above, may have contributed to the development of vitamin B₁₂ deficiency in our patients. This may argue against the late introduction of solids (after six months of age) into infant diets.

Prognosis

Although vitamin B₁₂ deficiency is relatively rare, it is important to recognize the disorder, given the potentially serious neurologic outcomes. As seen in our two patients and in multiple case reports, most clinical features of vitamin B₁₂ deficiency resolve quickly with repletion of vitamin B₁₂. The neurologic findings generally improve within weeks, and imaging (i.e., MRI of the brain) returns to normal within a few months. Long-term prognosis after B₁₂ repletion and supplementation is less clear. Cognitive and developmental delays have been reported. In one case series of six infants with nutritional B₁₂ deficiency, two had poor intellectual outcomes in terms of motor and language delay at four and five years.²⁴,²⁵ However, the developmental prognosis of these children months and years later is based only on a few case reports with an unclear duration of B₁₂ supplementation; more follow-up research is needed to further clarify outcome.

Table 3: Sources of dietary vitamin B₁₂

<table>
<thead>
<tr>
<th>Food</th>
<th>Vitamin B₁₂, µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortified cereal, 1 oz</td>
<td>0.6–6.0</td>
</tr>
<tr>
<td>1 large egg, 50 g</td>
<td>0.5</td>
</tr>
<tr>
<td>Cow’s milk, 1/2 cup</td>
<td>0.4–0.5</td>
</tr>
<tr>
<td>Fortified soy milk, 1/2 cup</td>
<td>0.4–1.6</td>
</tr>
<tr>
<td>Fortified nutritional yeast,*1 tbsp</td>
<td>1.5</td>
</tr>
<tr>
<td>Fortified meat analog</td>
<td>0.5–1.2</td>
</tr>
</tbody>
</table>

Source: Package information and US Department of Agriculture’s Nutrient Database.²⁴ *Not all yeasts are fortified.

CMAJ, October 2, 2012, 184(14) 1597
References


Affiliations: From the Department of Pediatrics (Roumeliotis), Centre Hospitalier Ste-Justine, Montreal, Que.; and the Department of Pediatrics (Roumeliotis, Dix, Lipson), BC Children’s Hospital, Vancouver, BC.

Contributors: All of the authors contributed to the conception of this article. The manuscript was drafted by Nadia Roumeliotis and revised critically by Alissa Lipson and David Dix for clinical expertise and intellectual content. All of the authors approved the final version of the article submitted for publication.

Acknowledgements: The authors thank Dr. Louis Wadsworth, Dr. Jason Ford and Dr. Michael Sargent from BC Children’s Hospital for their help with this article.

CMAJ remains committed to notifying readers in a timely way about advisories and warnings pertaining to serious adverse drug events. A collection of recent drug advisories from Health Canada and the US Food and Drug Administration is regularly updated at www.cmaj .ca/misc/advisories.xhtml.